{"url_path":"/sec/sls/8-k/2026-06-02/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 ****Other Events**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-02","source_url":"https://www.sec.gov/Archives/edgar/data/1390478/0001104659-26-069251-index.html","accession_number":"0001104659-26-069251","cik":"0001390478","ticker":"SLS","issuer_name":"SELLAS Life Sciences Group, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1390478/0001104659-26-069251-index.html","primary_entity_key":"0001390478","primary_entity_name":"SELLAS Life Sciences Group, Inc."},"word_count":65,"has_tables":true,"body_markdown":"**Item 8.01****Other Events**\n\n \n\nAs previously reported, as of March 31, 2026,\nSELLAS Life Sciences Group, Inc. (the “Company”) had $107.1 million of cash and cash equivalents.\n\n \n\nSubsequent to March 31, 2026, in April and May\n2026, the Company received approximately $28.7 million in proceeds from the exercise of common stock warrants.\n\n \n\nAs of June 2, 2026, the Company had 196,632,574\nshares of common stock outstanding."}